Shares of Trovagene Inc. (NASDAQ:TROV) were up 2.5% during trading on Wednesday . The stock traded as high as $5.98 and last traded at $5.73, with a volume of 783,787 shares. The stock had previously closed at $5.59.

Several analysts have recently commented on TROV shares. Maxim Group reissued a “buy” rating on shares of Trovagene in a research note on Monday, June 6th. Cantor Fitzgerald raised Trovagene from a “hold” rating to a “buy” rating and increased their price objective for the stock from $5.00 to $7.00 in a research note on Monday, August 8th. Piper Jaffray Cos. downgraded Trovagene from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $5.26 to $8.00 in a research note on Monday, April 25th. Leerink Swann reissued a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Finally, Zacks Investment Research raised Trovagene from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Trovagene has a consensus rating of “Hold” and a consensus target price of $7.13.

The company’s 50 day moving average price is $5.21 and its 200 day moving average price is $4.95. The firm’s market capitalization is $170.03 million.

Trovagene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.03. On average, analysts anticipate that Trovagene Inc. will post ($1.33) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.